Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1178 • ACR Convergence 2020
Associations of Walking Endurance and Speed with Multiple Measures of Subclinical Cardiovascular Disease in Rheumatoid Arthritis
Genna Braverman¹, Sabahat Bokhari², Kazato Ito³, Joan Bathon² and Jon Giles⁴, ¹NY Presbyterian - Columbia University Irving Medical Center, New York, NY, ²Columbia University, Vagelos College of Physicians and Surgeons, New York, NY, ³Division of Cardiology, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, ⁴Columbia University, New York, NY
Background/Purpose: The 400 meter timed walk test has been studied as a simple summary measure of fitness that is predictive of mobility limitation and incident…
Abstract Number: 1194 • ACR Convergence 2020
MUC5B Promoter Variant rs35705950 and Risk Stratification for Rheumatoid Arthritis – Interstitial Lung Disease
Pierre-Antoine Juge¹, Fabienne Louis-Sidney², Benjamin Granger³, Joanna Kedra⁴, Marie-Pierre Debray⁵, Esther Ebstein¹, Raphaël Borie⁶, Arnaud Constantin⁷, Bernard Combe⁸, Rene-Marc Flipo⁹, Xavier Mariette¹⁰, Olivier Vittecoq¹¹, Alain Saraux¹², Guillermo Carvajal Alegria¹³, Jean Sibilia¹⁴, Francis Berenbaum¹⁵, Caroline Kannengiesser¹⁶, Bruno Crestani⁶, Catherine Boileau¹⁶, Bruno Fautrel¹⁷ and Philippe Dieude¹⁸, ¹Université de Paris, Service de Rhumatologie Hôpital Bichat-Claude Bernard, AP-HP, Paris, France, ²Service de Rhumatologie, CHU de Fort de France, Martinique, France, Fort de France, France, ³Département de Biostatistiques, Santé Publique et Information Médicale, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Pitié-Salpêtrière, Paris, France., Paris, France, ⁴Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, UMR S1136, Paris, France, Paris, France, ⁵Université de Paris, Service de Radiologie Hôpital Bichat-Claude Bernard, AP-HP, Paris, France, ⁶Université de Paris, Service de Pneumologie Hôpital Bichat-Claude Bernard, AP-HP, Paris, France, ⁷Hospital Pierre Paul Riquet, Toulouse, France, ⁸University of Montpellier, Montpellier, France, ⁹Lille University Hospital, Lille, France, ¹⁰Paris-Sud University, Rueil-Malmaison, France, ¹¹University Hospital of Rouen, Rouen, France, ¹²Department of Rheumatology, UBO, CHU, INSERM 1227 (LBAI), Brest, France, ¹³CHU de Brest, Service de Rhumatologie, Brest, France, ¹⁴CHU Strasbourg, Service de Rhumatologie, Strasbourg, France, ¹⁵AP-HP, Hôpital Saint-Antoine, Service de Rhumatologie, Centre de Recherche Saint-Antoine, INSERM UMR_S 938,Sorbonne Université, Paris, 75012, France, Paris, France, ¹⁶Université de Paris, Hôpital Bichat, Service de Génétique, AP-HP, Paris, Paris, France, ¹⁷Sorbonne University, INSERM, IPLES; Pitié-Salpêtrière Hospital, Paris, Ile-de-France, France, ¹⁸Université de Paris, Service de Rhumatologie Hôpital Bichat-Claude Bernard, AP-HP, Paris, Ile-de-France, France
Background/Purpose: Interstitial lung disease (ILD) is an extra-articular manifestation of rheumatoid arthritis (RA) detected in 20 to 60% of patients with RA on high-resolution computed-tomography…
Abstract Number: 1210 • ACR Convergence 2020
Patient-Reported Outcomes Measurement Information System (PROMIS) Assessment of Response to Treatment with Golimumab IV or Infliximab in Rheumatoid Arthritis Patients: Results from a Phase 4 Study
Clifton Bingham III¹, Shelly Kafka², Shawn Black², Stephen Xu³, Wayne Langholff⁴ and Jeffrey R Curtis⁵, ¹Johns Hopkins University, Baltimore, MD, ²Janssen Scientific Affairs, LLC, Horsham, PA, ³Janssen Research & Development, LLC, Spring House, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: AWARE (Comparative & Pragmatic Study of Golimumab [GLM] Intravenous [IV] vs Infliximab [IFX] in RA) is a Phase 4 study designed to provide a…
Abstract Number: 1227 • ACR Convergence 2020
Reduction in Peripheral CD19+ CD27- Naïve B Cells Is Associated with Clinical Remission in Patients with Rheumatoid Arthritis Receiving Combined Treatment with Methotrexate and TNF Inhibitors
Borja Hernandez-Breijo¹, Chamaida Plasencia², Victoria Navarro-Compán³, Israel Nieto-Gañán⁴, Cristina Sobrino⁵, Ana Martínez-Feito⁶, Carlota García-Hoz⁴, Paloma Lapuente-Suanzes⁴, Javier Bachiller-Corral⁷, Gema Bonilla², Cristina Pijoán-Moratalla⁷, Garbiñe Roy⁴, Mónica Vázquez⁷, Alejandro Balsa², Luisa M Villar⁴, Dora Pascual-Salcedo⁸ and Eulalia Rodríguez-Martín⁴, ¹Immuno-rheumatology Research group. IdiPAZ. La Paz University Hospital, Madrid, Spain, ²Rheumatology, La Paz University Hospital-IdiPAZ, madrid, Spain, ³Hospital Universitario La Paz IdiPaz, Madrid, Pais Vasco, Spain, ⁴Hospital Universitario Ramón y Cajal-IRYCIS, Madrid, Spain, ⁵Hospital Ramón y Cajal-IRYCIS, Madrid, Spain, ⁶Hospital Unversitario La Paz- idipaz, Madrid, Spain, ⁷Rheumatology, Hospital Universitario Ramón y Cajal, Madrid, Spain, ⁸Hospital Universitario La Paz- Idipaz, Madrid, Spain
Background/Purpose: Biological therapies, as TNF inhibitors (TNFi) are increasing remission rates in rheumatoid arthritis (RA) patients although these are still limited. This study aims to…
Abstract Number: 1402 • ACR Convergence 2020
Galectin-3 Decreases the Activity of 4-1BB by Facilitating Its Decoy Surface Binding in Rheumatoid Arthritis
Morten Aagaard Nielsen¹, Kristian Juul-Madsen², John Stegmayr³, Chao Gao⁴, Tue Wenzel Kragstrup¹, Malene Hvid¹, Thomas Vorup-Jensen¹, Richard Cummings⁵, Hakon Leffler³ and Bent Deleuran¹, ¹Aarhus University, Aarhus, Denmark, ²Aarhus University, Aarhus, Midtjylland, Denmark, ³Lund University, Lund, Sweden, ⁴Beth Israel Deaconess Medical Center Harvard Medical School, Boston, MA, ⁵Beth Israel Deaconess Medical Center Harvard Medical School, Boston
Background/Purpose: Orchestration of immune checkpoints is central for the outcome of immune activation, especially in patients with rheumatoid arthritis (RA). We have previously shown that…
Abstract Number: 1499 • ACR Convergence 2020
The Frequency of Contraception Documentation in Women with Lupus and Rheumatoid Arthritis Within the RISE Registry
Megan Clowse¹, Jing Li², Amanda Eudy³, Mehret Birru Talabi⁴ and Gabriela Schmajuk⁵, ¹Duke University, Chapel Hill, NC, ²University of California, San Francisco, San Francisco, CA, ³Duke University, Durham, NC, ⁴University of Pittsburgh, Pittsburgh, PA, ⁵University of California, San Francisco, Atherton, CA
Background/Purpose: Several of the most commonly prescribed anti-rheumatic medications for women with rheumatic disease are known teratogens, posing a risk for pregnancy loss and birth…
Abstract Number: 1558 • ACR Convergence 2020
Cinematic Rendering Enables Depiction of Bone Anabolic Effects in Patients Treated with Baricitinib
Sara Bayat¹, David Simon², Louis Schuster², Georg Schett³ and Arnd Kleyer², ¹Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, ²Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Bayern, Germany, ³Friedrich-Alexander-Universität Erlangen- Nuremberg, Erlangen, Germany
Background/Purpose: Preclinical studies show that tsDMARDs such as baricitinib may be a therapeutic agent for bone anabolic effects by increasing osteoblast function in inflammatory conditions.[1]…
Abstract Number: 1713 • ACR Convergence 2020
Exploring Novel Tenosynovitis and Combined Inflammation Imaging Outcomes: Results from a Randomized Controlled Trial in Early Rheumatoid Arthritis
Philip G Conaghan¹, Mikkel Østergaard², Orrin Troum³, Zhiyong Xie⁴, Alan Brett⁵, Mark Snyder⁶, Abbas Ebrahim⁶, Douglass S Chapman⁷, Gosford A Sawyerr⁸ and John Andrews⁶, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and National Institute for Health Research Leeds Biomedical Research Centre, Leeds, United Kingdom, ²Rigshospitalet, University of Copenhagen, Copenhagen, Denmark, ³Division of Rheumatology, University of Southern California Keck School of Medicine, Santa Monica, CA, ⁴Pfizer Inc, Groton, CT, ⁵Imorphics Ltd, Manchester, United Kingdom, ⁶Pfizer Inc, Collegeville, PA, ⁷Pfizer Inc, New York, NY, ⁸Syneos Health, -
Background/Purpose: MRI trial outcomes have largely focused on synovitis, bone marrow edema (BME), and erosions. Tenosynovitis is a common manifestation of RA, but is relatively…
Abstract Number: 1729 • ACR Convergence 2020
Associations Between Patient Reported Outcomes and Impairments of Work and Activity in Patients with Rheumatoid Arthritis Who Achieved Clinical Remission; Retrospective Analysis Using the IORRA Database
Ryoko Sakai¹, Eiichi Tanaka², Eisuke Inoue³, Minako Sato⁴, Masaru Tanaka⁴, Katsunori Ikari¹, Atsuo Taniguchi¹, Hisashi Yamanaka⁵ and Masayoshi Harigai⁶, ¹Tokyo Women’s Medical University School of Medicine, Tokyo, Japan, ²Department of Rheumatology, Tokyo Women’s Medical University School of Medicine, Tokyo, Japan, ³Department of Rheumatology, Tokyo Women’s Medical University School of Medicine; Showa University Research Administration Center, Showa University, Tokyo, Japan, ⁴Eli Lilly Japan K.K., Tokyo, Japan, ⁵Sanno Medical Center, Tokyo, Japan, Tokyo, Japan, ⁶Department of Rheumatology, Tokyo Women’s Medical University School of Medicine, Shinjuku-ku, Tokyo, Japan
Background/Purpose: Disease burden and subjective symptoms of rheumatoid arthritis (RA) remain even after achieving clinical remission or low disease activity. Impairments to work and societal/daily…
Abstract Number: 1746 • ACR Convergence 2020
Association of Obesity with Treatment Response to Methotrexate or Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis
Dilli Poudel¹, Ted Mikuls², Michael George¹, Bryant England², Grant Cannon³, Brian Sauer⁴ and Joshua Baker¹, ¹University of Pennsylvania, Philadelphia, PA, ²University of Nebraska Medical Center, Omaha, NE, ³Salt Lake City VA Medical Center and University of Utah, Salt Lake City, ⁴University of Utah, Omaha, NE
Background/Purpose: Obesity affects 30-40% of RA patients and is associated with higher clinical disease activity measures and progressive disability. Studies suggest that obesity may be…
Abstract Number: 1763 • ACR Convergence 2020
Blending Hierarchical Cluster Analysis and Cluster-Specific Regressions to Predict Clinical Outcome to Tofacitinib Treatment in Patients with Rheumatoid Arthritis
Robert Landewé¹, Daniel H Solomon², Gianluca Bonfanti³, Luigi Manca³, John C Woolcott⁴, Jasper Deuring⁵, Stephen Watt⁶, Pritha Bhadra Brown⁶, Rebecca Germino⁶, Birol Emir⁶ and Roger A Edwards⁷, ¹Amsterdam University Medical Center & Zuyderland Hospital, Amsterdam, Netherlands, ²Brigham and Women's Hospital, Boston, MA, ³Fair Dynamics Consulting, SRL, Milan, Italy, ⁴Pfizer Inc, Collegeville, PA, ⁵Pfizer Inc, Rotterdam, Netherlands, ⁶Pfizer Inc, New York, NY, ⁷Health Services Consulting Corporation, Boxborough, MA
Background/Purpose: Patients with RA exhibit wide variations in response to therapy. Early treatment response profiles may help us to better predict subsequent treatment response, thus…
Abstract Number: 1976 • ACR Convergence 2020
High Disease Activity Is Associated with Incident Osteoporotic Fractures Among Veterans with Rheumatoid Arthritis
Katherine Wysham¹, Ted Mikuls², Bryant England², Dolores Shoback³, Patricia Katz⁴, Jose Garcia¹, Brian Sauer⁵, Beth Wallace⁶, John Richards⁷, Paul Monach⁸, Grant Cannon⁹ and Joshua Baker¹⁰, ¹VA Puget Sound/University of Washington, Seattle, WA, ²University of Nebraska Medical Center, Omaha, NE, ³San Francisco VA/University of California, San Francisco, San Francisco, CA, ⁴University of California, San Francisco, Novato, CA, ⁵University of Utah, Omaha, NE, ⁶Michigan Medicine, VA Ann Arbor Healthcare System Center for Clinical Management Research, Ann Arbor, MI, ⁷Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA, ⁸Brigham and Women's, Boston, ⁹Salt Lake City VA Medical Center and University of Utah, Salt Lake City, ¹⁰University of Pennsylvania, Philadelphia, PA
Background/Purpose: Rheumatoid arthritis (RA) is a risk factor for osteoporosis and fractures yet the disease specific contributions to osteoporotic fractures (OFX) are not well understood.…
Abstract Number: 2006 • ACR Convergence 2020
Identification of a Rule to Predict Response to Sarilumab in Patients with Rheumatoid Arthritis Using Machine Learning and Clinical Trial Data
Markus Rehberg¹, Clemens Giegerich¹, Amy Praestgaard², Hubert van Hoogstraten³, Melitza Iglesias-Rodriguez², Jeffrey R Curtis⁴, Jacques-Eric Gottenberg⁵, Andreas Schwarting⁶, Santos Castañeda⁷, Andrea Rubbert Roth⁸ and Ernest Choy⁹, ¹Sanofi, Frankfurt, Germany, ²Sanofi, Cambridge, MA, ³Sanofi, Bridgewater, NJ, ⁴Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵Strasbourg University Hospital, Strasbourg, France, ⁶Johannes Gutenberg University, Mainz, Germany, ⁷Princesa University Hospital, Universidad Autónoma, Madrid, Madrid, Spain, ⁸Klinik für Rheumatologie, Kantonsspital St Gallen, St Gallen, Sankt Gallen, Switzerland, ⁹CREATE Centre, Cardiff University, Cardiff, Wales, United Kingdom
Background/Purpose: Despite the existence of guidelines for DMARD treatment of RA, a more individualized approach to treatment is needed to maximize efficacy while minimizing risk…
Abstract Number: 0030 • ACR Convergence 2020
Distinct DNA Methylation Patterns of Rheumatoid Arthritis Peripheral Blood and Synovial Tissue T Cells
Rizi Ai¹, Gary Firestein², David Boyle³ and Wei Wang⁴, ¹University of California San Diego, San Diego, CA, ²University of California, San Diego, La Jolla, CA, ³UCSD, La Jolla, CA, ⁴UCSD, La Jolla
Background/Purpose: To understand the epigenetic patterns of T cells accumulated in rheumatoid arthritis (RA) synovium, we characterized DNA methylation of CD3+ T cells in peripheral…
Abstract Number: 0084 • ACR Convergence 2020
Clinical Characteristics of Patients with Rheumatism of Juvenile Onset and Adult Onset in the BIOBADAGUAY Cohort
Natalia Cabrera¹, Vannia Valinotti², Gabriela Avila-Pedretti¹, Sonia Cabrera², Patricia Melgarejo³, Zoilo Morel⁴, Lourdes Roman², Pedro Babak⁴, Rodrigo Acosta², Romina Glitz⁴, Darwin Cordovilla⁵, Roger Rolon⁴, Magali Zanotti-Cavazzoni¹, Marco Antonio Franco Britos⁶, Marcos Vazquez², Pedro Delgadillo⁴, Isabel Acosta², María del Carmen Martinez⁴, Gabriel Elizaur⁴, María Teresa Romero⁴, Ernesto Paredes⁴, Paloma de Abreu¹ and Leticia Segovia⁷, ¹Sociedad Paraguaya de Reumatología, Asunción, Paraguay, ²Hospital de Clínicas, Asunción, Paraguay, ³Hospital IPS, Villa Rica, Paraguay, ⁴Hospital Central del Instituto de Previsión Social, Asunción, Paraguay, ⁵Instituto Nacional de Reumatología, Montevideo, Uruguay, ⁶Instituto de Previsi�n Social, Asunci�n, Central, Paraguay, ⁷Hospital del IPS, Asunción, Paraguay
Background/Purpose: The Paraguayan-Uruguayan cohort of patients with rheumatic inflammatory diseases (BIOBADAGUAY), collect clinical and epidemiological information on adults and children patients receiving biological therapies (BT).…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].